|
Based near Atlanta, Georgia, EndoChoice (NYSE: GI) focuses on the manufacturing and commercialization of technologies including endoscopic imaging systems, devices and infection control products, and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (FUSE®). EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc. |
|
|
FUSE® Endoscopy System is the latest patented technology of 330 degrees vs 170 degrees (old technology). This latest patented technology originates from the United States and will change the world of Endoscopy today and in the years to come. The full range of Product Solutions (including single use products) provided by Wellmedic Healthcare to the Endoscopy Department (in Government and Private Hospitals) will make us the main Endoscopy Solution Provider in Malaysia and neighboring countries.
This latest technology allows the doctor to view 94% more of the Colon surface area which indirectly translates to better chances of finding more pre-cancerous adenomas or polyps which would have been missed with the traditional forward viewing technology (170 degrees)(See Figure 1). This latest technology was also featured in the Lancet Oncology (power factor 25) and was clinically proven that doctors were able to detect 69% more polyps than a traditional forward viewing technology (170 degrees). |